Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Intervention: Losartan (Drug); Zileuton (Drug); N-Acetylcysteine (Drug); Pravastatin (Drug); Erythromycin (Drug)
Phase: Phase 1/Phase 2
Status: Terminated
Sponsored by: National Human Genome Research Institute (NHGRI) Official(s) and/or principal investigator(s): Thomas Markello, M.D., Principal Investigator, Affiliation: National Human Genome Research Institute (NHGRI)
Summary
This study will examine whether five drugs (pravastatin, Losartan, Zileuton,
N-acetylcysteine and erythromycin) used together can slow the course of pulmonary fibrosis
(scarring of the lung tissue) in patients with Hermansky-Pudlak Syndrome (HPS). Patients
with this disease have decreased skin color (albinism), bleeding problems, and sometimes
colon problems. Two of the known types of Hermansky Pudlak syndrome, type 1 and type 4, are
at high risk of pulmonary fibrosis between the ages of 30 and 50.
Patients 18 to 70 years of age who have Hermansky-Pudlak Syndrome with a serious loss of
lung function due to pulmonary fibrosis may be eligible for this study.
Participants begin taking pravastatin on study day 2 and start a new drug every 3 days.
Patients who experience no problems with the medicines return home and continue on the drugs
for the next 2 years. They return to the NIH Clinical Center every 3 months for a medical
history, physical examination, and blood, urine and lung function tests. CT and bone density
scans are done every year. The study may continue for up to 3 years.
Clinical Details
Official title: Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Survival at 2 Years
Detailed description:
Hermansky-Pudlak Syndrome (HPS) is a rare autosomal recessive disease consisting of
oculocutaneous albinism and a platelet storage pool defect. The most serious complication of
this disorder, pulmonary fibrosis, occurs only in genetic subtypes HPS-1 and HPS-4 and is
generally fatal in the fourth or fifth decade. HPS-1 is very common in northwest Puerto
Rico. There is no effective treatment for the pulmonary disease of HPS (HPS-PF), which
resembles idiopathic pulmonary fibrosis (IPF). A preliminary study of the antifibrotic drug,
pirfenidone, gave promising results for mild to moderate HPS-PF, but not for severe
pulmonary fibrosis. A second study is currently addressing only mild to moderate HPS-PF.
Other drugs, studied in IPF as single agents, have some efficacy for mild to moderate
disease, but none has had a major effect on mortality. Recently, a call has been made for
consideration of multi-drug therapy (i. e., an oncologic approach) for severe pulmonary
fibrosis. Based upon positive responses from companies producing relevant drugs, we propose
a multi-drug trial using five agents: Losartan, Zileuton, a generic statin (Pravastatin),
generic N-acetylcysteine, and generic Erythromycin. Participants with severe pulmonary
fibrosis will be drawn largely from the Puerto Rican population. Eligibility will require a
molecular diagnosis of HPS-1 or HPS-4, radiographic evidence of interstitial lung disease,
persistent pulmonary function testing less than or equal to 45% of predicted after
bronchodilation, and absence of other causes of lung dysfunction. Participants will be
admitted to the NIH Clinical Center for a 21-day admission to establish baseline function
and to begin medication therapy. Follow-up admissions (3 days) will occur every 3 months.
The primary outcome parameter will be survival at 2 years.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
- INCLUSION CRITERIA:
To be eligible for this protocol, participants must:
- Have a molecular diagnosis of HPS-1 or HPS-4
- Be 18-70 years of age
- Have the expectation to live more than 3 months, i. e., an FVC greater than or equal
to 30% of predicted
- Have evidence of severe pulmonary fibrosis, i. e.:
1. A FVC less than or equal to 45% of predicted
2. Reduced exercise tolerance lasting longer than 1 week on the Dyspnea Perception
Scale
3. No evidence of improvement in pulmonary fibrosis within the past year, as
defined by an FVC increase of 10% or a DLco increase of 15%.
- Be available, willing, and able to come to the NIH Clinical Center for admission
every 3 months.
EXCLUSION CRITERIA:
- An explanation for interstitial lung disease other than HPS, including but not
limited to radiation, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis
obliterans organizing pneumonia, cancer
- Pregnancy or lactation
- History of ethanol abuse or recreational drug use in the past two years
- History of human immunodeficiency virus (HIV) or chronic viral hepatitis infection
- Chronic use of high-dose steroids (greater than 10 mg prednisone/day) intended for
ongoing treatment of their interstitial lung disease
- Use of any of the following within 28 days of enrollment: investigational therapy,
cytotoxic/immunosuppressive agents other than corticosteroids, including but not
limited to azathioprine, cyclosphosphamide, methotrexate, cyclosporine, colchicine,
interferon gamma-1b, bosentan;
- Any severe medical complication including but not be limited to uncontrolled
seizures, repeated transient ischemic attacks, severe ataxia, uncontrolled migraine
headaches, diplopia, repeated episodes of syncope, an untreated psychiatric disorder,
recent myocardial infarction (past 6 months), unstable angina, clinically relevant
and untreated arrhythmias, uncontrolled hypotension or hypertension (systolic blood
pressure less than 80 or greater than 180 mm Hg), myocarditis, severe congestive left
sided heart failure, hepatomegaly not due to right heart failure, renal glomerular
impairment (creatinine clearance less than 35 ml/min/1. 73 m(2)), pancreatitis, toxic
thyroiditis, life-threatening malignancy;NOTE: right sided heart failure due to
pulmonary hypertension as a result of pulmonary fibrosis will not be considered an
exclusion criteria.
- Significant laboratory abnormalities, including but not limited to serum potassium
less than 3. 0 or greater than 5. 4 mEq/L, SGPT greater than 100 U/L, CK greater than
700 U/L, hemoglobin less than 9. 0 g/dL, platelets less than 70 k/mm(3), leukocyte
count less than 2. 0 k/microL;
- For women of child-bearing age, failure to have an effective method of birth control.
Oral contraceptives will be considered inadequate without a second method due to
risk of reduced efficacy of BCP while taking Zileuton.
- Severe psychiatric disease untreated. Inability to give informed consent after
reading or having the consent read to the participant in their native language. Any
concern that there is a therapeutic misconception will be evaluated by genetic
counselor and/or appropriate mental health professionals prior to acceptance into the
study
Locations and Contacts
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
Additional Information
Related publications: Witkop CJ, Nuñez Babcock M, Rao GH, Gaudier F, Summers CG, Shanahan F, Harmon KR, Townsend D, Sedano HO, King RA, et al. Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med P R. 1990 Aug;82(8):333-9. HERMANSKY F, PUDLAK P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959 Feb;14(2):162-9. Huizing M, Gahl WA. Disorders of vesicles of lysosomal lineage: the Hermansky-Pudlak syndromes. Curr Mol Med. 2002 Aug;2(5):451-67. Review. Gahl WA, Huizing M. Hermansky-Pudlak Syndrome. 2000 Jul 24 [updated 2014 Dec 11]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from http://www.ncbi.nlm.nih.gov/books/NBK1287/
Starting date: April 2007
Last updated: June 3, 2013
|